.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,429,394

« Back to Dashboard

Details for Patent: 7,429,394

Title:Ion binding compositions
Abstract: The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides core-shell compositions and pharmaceutical compositions thereof. Methods of use of the core-shell compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of phosphate imbalance disorders, hypertension, chronic heart failure, end stage renal disease, liver cirrhosis, chronic renal insufficiency, fluid overload, or sodium overload.
Inventor(s): Charmot; Dominique (Campbell, CA), Fordtran; John (Dallas, TX), Chang; Han Ting (Livermore, CA), Connor; Eric (Los Gatos, CA), Liu; Mingjun (Santa Clara, CA), Klaerner; Gerrit (San Jose, CA)
Assignee: Relypsa, Inc. (Santa Clara, CA)
Filing Date:Mar 30, 2005
Application Number:11/095,918
Claims:1. A pharmaceutical composition comprising core-shell particles and a pharmaceutically acceptable excipient, said core-shell particles comprises a core component encapsulated in a shell component, said core component comprising a potassium binding polymer, said shell component comprising a crosslinked amine functional polymer alkylated with hydrophobic agent(s), said core-shell particles having a capacity for binding potassium ion in a gastrointestinal tract of an animal subject and retaining a significant amount of said bound potassium ion during a period of residence of the core-shell particles in the gastrointestinal tract of the animal subject.

2. The pharmaceutical composition of claim 1 wherein the core component comprises crosslinked carboxylate, phosphonate, sulfate, sulfonate, sulfamate polymers or combinations thereof.

3. A pharmaceutical composition comprising core-shell particles and a pharmaceutically acceptable excipient, said core-shell particles comprises a core component encapsulated in a shell component, said core component comprising a potassium binding polymer, said shell component comprising a crosslinked amine functional polymer alkylated with hydrophobic agent(s).

4. The pharmaceutical composition of claim 3 wherein the alkylating agents have the formula RX where R is a C.sub.1-C.sub.20 alkyl, C.sub.1-C.sub.20 hydroxy-alkyl, C.sub.6-C.sub.20 aralkyl, C.sub.1-C.sub.20 alkylammonium, or C.sub.1-C.sub.20 alkylamido group and X comprises one or more electrophilic groups.

5. The pharmaceutical composition of claim 3 wherein the alkylating agent is an alkyl or alkylaryl group carrying an amine-reactive electrophile.

6. The pharmaceutical composition of claim 3 wherein the alkylating agent is selected from the group consisting of benzyl halide and dodecyl halide.

7. The pharmaceutical composition of claim 3 wherein the alkylating agent includes at least two electrophilic groups X.

8. The pharmaceutical composition of claim 7 wherein the alkylating agent is selected from the group consisting of di-haloalkane, dihalopolyethylene glycol, and epichlorohydrin.

9. The pharmaceutical composition of claim 3 wherein the core component comprises crosslinked carboxylate, phosphonate, sulfate, sulfonate, sulfamate polymers or combinations thereof.

10. The pharmaceutical composition of claim 3 wherein the shell thickness is from about 0.002 .mu.m to about 50 .mu.m.

11. The pharmaceutical composition of claim 3 wherein the shell to core weight ratio is 0.01% to 50%.

12. The pharmaceutical composition of claim 3 wherein the size of the core-shell particle is from about 200 nm to about 2 mm.

13. The pharmaceutical composition of claim 3 for the treatment of hyperkalemia, depressed renal synthesis of calcitriol, renal insufficiency, hypertension, chronic heart failure, end stage renal disease, fluid overload, renal insufficiency, and anabolic metabolism.

14. The pharmaceutical composition of claim 3 wherein the pharmaceutically acceptable excipient is one or more pharmaceutically acceptable carriers or diluents, and further optionally comprises additional therapeutic agents.

15. A pharmaceutical composition comprising core-shell particles and a pharmaceutically acceptable excipient, said core-shell particles comprises a core component encapsulated in a shell component, said core component comprising a crosslinked potassium binding polymer, said shell component comprising a crosslinked amine functional polymer alkylated with an alkyl or alkylaryl group.

16. The pharmaceutical composition of claim 15, the core component comprising crosslinked carboxylate, phosphonate, sulfate, sulfonate, sulfamate polymers or combinations thereof.

17. The pharmaceutical composition of claim 15 wherein the shell thickness is from about 0.002 .mu.m to about 50 .mu.m.

18. The pharmaceutical composition of claim 15 wherein the alkylating agent is a benzyl halide.

19. The pharmaceutical composition of claim 17 wherein the size of the core-shell particle is from about 200 nm to about 2 mm.

20. The pharmaceutical composition of claim 19 wherein the alkylating agent is a benzyl halide.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc